Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
Executive Summary
- Devonian Health Group reported Q1 2025 net loss of $1.6 M ($0.01 per share) and an 83% decline in distribution revenues to $1.05 M versus $6.12 M a year earlier.
- The company completed a private‑placement financing raising $2.7 M through units (common shares and warrants), bringing cash on hand to $6.6 M.
- Clinical progress: Phase 2/3 pediatric atopic dermatitis study protocol finalized and ready for regulatory approval; pivotal radiodermatitis study being prepared; ongoing preclinical work in MASH and fibrosis.
Key Details
- Financial Highlights
- Gross margin on distribution revenues: $0.5 M.
- Distribution revenues Q1 2025: $1.05 M (‑83% YoY).
- Net loss Q1 2025: $1.6 M vs. $0.6 M in Q1 2024.
- Operating cash outflow: $2.3 M (vs. $2.6 M generated in prior year).
- Cash & cash equivalents at quarter end: $6.6 M (down from $7.0 M on July 31 2025).
-
Debt‑free status maintained.
-
Financing
- Private placement of units (common shares + warrants) raised $2.7 M gross proceeds.
- Units issued at undisclosed per‑unit price; included warrant component (terms not specified).
-
Proceeds allocated to bolster liquidity and fund ongoing clinical/preclinical programs.
-
Clinical & Preclinical Updates
- Thykamine™ Phase 2/3 Pediatric Atopic Dermatitis Study: protocol finalized for a 12‑week, multicenter, randomized, double‑blind, vehicle‑controlled trial testing two cream strengths (0.05% & 0.1%) applied twice daily to patients aged 3 months–17 years; study pending regulatory approval.
- Radiodermatitis Pivotal Study: design underway for a double‑blind, randomized, Glaxal‑based controlled multicenter trial in breast‑cancer patients receiving radiation therapy.
-
Preclinical Programs: continued investigations of Thykamine™ in MASH (metabolic associated steatohepatitis) and fibrosis; additional studies launched to explore anti‑fibrotic potential.
-
Corporate Governance
-
On 26 Nov 2025, Pierre Labbé appointed to the Board of Directors, replacing Jean Forcione (resigned 30 Sep 2025).
-
Operational Note
- Distribution revenue decline attributed to expiry of Dexlansoprazole distribution agreement in April 2025.
Notable Quotes
“We are very pleased with the continued momentum across both our therapeutic and commercial activities this quarter… The successful completion of $2.7 million in private placements reflects growing confidence in our strategy and in the long‑term value of our pipeline,” – Dr. André Boulet, CEO
Materiality Assessment: Material – Negative (significant earnings decline, revenue drop, but also material financing and clinical milestones).